Literature DB >> 12010423

Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.

S Lacroix-Desmazes1, N Misra, J Bayry, C Artaud, B Drayton, S V Kaveri, M D Kazatchkine.   

Abstract

The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors. We briefly conclude on the avenues that remain to be explored in order to establish efficient therapeutic approaches aimed at eliminating FVIII inhibitors in patients with haemophilia A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010423     DOI: 10.1046/j.1365-2516.2002.00624.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.

Authors:  Yan Su; Robert Rossi; Anne S De Groot; David W Scott
Journal:  J Leukoc Biol       Date:  2013-05-31       Impact factor: 4.962

2.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

Authors:  Leonard Moise; Chang Song; William D Martin; Ryan Tassone; Anne S De Groot; David W Scott
Journal:  Clin Immunol       Date:  2011-12-08       Impact factor: 3.969

Review 3.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 4.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

Authors:  Pauline A van Schouwenburg; Theo Rispens; Gerrit Jan Wolbink
Journal:  Nat Rev Rheumatol       Date:  2013-02-12       Impact factor: 20.543

5.  Population-specific design of de-immunized protein biotherapeutics.

Authors:  Benjamin Schubert; Charlotta Schärfe; Pierre Dönnes; Thomas Hopf; Debora Marks; Oliver Kohlbacher
Journal:  PLoS Comput Biol       Date:  2018-03-02       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.